J1437 HCPCS code: Injection, ferric derisomaltose, 10 mg
J1437 is the HCPCS Level II code for injection, ferric derisomaltose, 10 mg. In 2024 Medicare paid an average of $15.76 per service for J1437 across 4,340,076 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 100 per day on outpatient hospital claims. Medicare volume rose 390% from 2022 to 2024 (885,360 to 4,340,076 services). In 2024, about 2,542 clinicians billed Medicare for J1437 for 33,356 beneficiaries; Florida, Tennessee, Maryland accounted for 35% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2020-10-01 |
| Last action effective | 2023-01-01 |
Who bills J1437 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 2,542 |
| Medicare beneficiaries | 33,356 |
| States with claims | 44 |
| Share of services in top 3 states (Florida, Tennessee, Maryland) | 35% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J1437, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 885,360 | 6,758 | $23.17 | $18.46 |
| 2023 | 2,560,139 | 19,962 | $20.68 | $16.46 |
| 2024 | 4,340,076 | 33,356 | $19.82 | $15.76 |
States with the most J1437 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 743,317 | $15.77 |
| Tennessee | 426,650 | $15.89 |
| Maryland | 359,765 | $15.69 |
| Pennsylvania | 285,320 | $15.74 |
| Texas | 281,199 | $16.08 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 100 | Prescribing Information |
| practitioner claims | 100 | Prescribing Information |
What changed for J1437
- 2020-10-01: J1437 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1437?
J1437 is the HCPCS Level II code for injection, ferric derisomaltose, 10 mg. Short descriptor: "Inj. fe derisomaltose 10 mg".
How much does Medicare pay for J1437?
In 2024, the average Medicare payment was $15.76 per service (average allowed $19.82).
Does Medicare cover J1437?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J1437 can be billed per day?
100 on outpatient hospital claims; 100 on practitioner claims (NCCI medically unlikely edits).
Related J14 codes
- J1410 — Injection, estrogen conjugated, per 25 mg
- J1411 — Injection, etranacogene dezaparvovec-drlb, per therapeutic dose
- J1412 — Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2 x 10^13 vector genomes
- J1413 — Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
- J1414 — Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
- J1426 — Injection, casimersen, 10 mg
- J1427 — Injection, viltolarsen, 10 mg
- J1428 — Injection, eteplirsen, 10 mg
- J1429 — Injection, golodirsen, 10 mg
- J1430 — Injection, ethanolamine oleate, 100 mg
- J1434 — Injection, fosaprepitant (focinvez), 1 mg
- J1435 — Injection, estrone, per 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1437
- Watch J1437 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1437
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.